Emergent BioSolutions (EBS) Tops Q4 EPS by 15c; Guides Revs Above the Street

Emergent BioSolutions (NYSE: EBS) reported Q4 EPS of $0.67, $0.15 better than the analyst estimate of $0.52. Revenue for the quarter came in at $138 million versus the consensus estimate of $126.9 million.

Emergent BioSolutions sees FY2014 revenue of $440-460 million, versus the consensus of $443.14 million.

"Our business performance to date has been strong based on our expanded product portfolio, growing contract manufacturing operations and robust contracts, grants and collaboration funding," said Daniel J. Abdun-Nabi, President and Chief Executive Officer of Emergent BioSolutions. "Given this performance and our outlook for the remainder of the year, we are increasing our full year 2014 revenue forecast to $440 to $460 million, increasing our GAAP net income forecast to $35 to $45 million and increasing our non-GAAP adjusted net income forecast to $50 to $60 million."

For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.

You May Also Be Interested In

• Gilead Sciences (GILD) Misses Q1 EPS by 288c
• South Plains Financial Inc. (SPFI) Tops Q1 EPS by 6c
• ResMed (RMD) Tops Q3 EPS by 20c